One of them, a randomized, double-blind, placebo-controlled phase II study on 192 patients, showed that enteral talactoferrin (recombinant human lactoferrin, TLF) significantly reduced mortality in patients with severe sepsis [181], while a phase II/III clinical trial conducted in a similar regimen on 305 patients did not confirm this, and even reported increased mortality in the TLF-treated group [182]. This evidence concerns the gene LTF and Sepsis.